Alex De Windt

Alex De Windt, MD has a diverse work experience in the field of drug safety, pharmacovigilance, and medical affairs. Starting in 2000, Dr. De Windt held positions at various pharmaceutical and biotech companies, including Bristol-Myers Squibb, i3 Research, Keog Pharma, Inc, Icon Clinical Research, Takeda Pharmaceuticals, Baxalta (now part of Shire), and Constellation Pharmaceuticals. These roles included positions such as Sr. Manager, Medical Affairs; Associate Director; Executive Director, Medical & Scientific Affairs; Director, Medical & Safety Services; Medical Director, Pharmacovigilance; and Executive Medical Director, Head of Pharmacovigilance/PV Consultant. In 2016, Dr. De Windt became the Managing Principal at Ajattele. Most recently, in 2022, Dr. De Windt joined Ardelyx, Inc. as the Vice President, Drug Safety.

Alex De Windt, MD attended Eugenio Maria De Hostos University, where they obtained a Medical Doctor degree. Their field of study during their time at the university is unknown. Additionally, they have also had a period of education at Grady Memorial Hospital, although the degree obtained and field of study during this time are unspecified.